Study of pancreas cancer and related conditions in Quebec
Quebec Pancreas Cancer Study
This study is trying to learn more about pancreas cancer and related conditions by collecting information from patients and their families to see how genetics and other factors might affect these cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Locations | 1 site (Montréal, Quebec) |
| Trial ID | NCT04104230 on ClinicalTrials.gov |
What this trial studies
The Quebec Pancreas Cancer Study is a prospective observational study that collects clinical, family history, and epidemiological data from patients diagnosed with pancreas cancer, related cancers, or pre-cancerous conditions, along with their families. The study aims to investigate the epidemiology of these conditions, assess hereditary cancer syndromes, and identify genetic and epigenetic changes associated with pancreas cancer. Additionally, it seeks to explore tumor biology and identify biomarkers linked to these cancers. By analyzing biospecimens and clinical data, the study hopes to uncover associations between biological changes and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with pancreatic cancer, related cancers, or high-risk individuals with specific hereditary cancer syndromes.
Not a fit: Patients without a diagnosis of pancreatic cancer or related conditions, or those not meeting the high-risk criteria, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of pancreas cancer and lead to improved risk assessment and targeted prevention strategies for patients.
How similar studies have performed: Other studies focusing on the genetic and epidemiological aspects of pancreas cancer have shown promise, indicating that this approach is supported by previous research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individual diagnosed with pancreatic cancer. * Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer, duodenal cancer, gallbladder cancer). * Individual diagnosed with pancreatic neoplasm or pancreatic cyst. * High-risk individuals with Familial Pancreatic Cancer (3 or more relatives affected with adenocarcinoma). * High-risk individuals with 2 first-degree relatives affected with young-onset pancreatic adenocarcinoma (≤ 50 years old). * High-risk individuals with one of the following Hereditary Cancer Syndromes: Peutz-Jeghers Syndrome (STK11 gene mutation), Familial Atypical Multiple Mole Melanoma Syndrome (CDKN2A gene mutation), or Hereditary Pancreatitis (PRSS1 gene mutation) with clinical manifestations. * High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITH a family history of cancer. Exclusion Criteria: * High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITHOUT a family history of cancer.
Where this trial is running
Montréal, Quebec
- McGill University Health Centre — Montréal, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Adeline Cuggia, MSc
- Email: cancer.pancreas@mcgill.ca
- Phone: 514-934-1934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.